Evotec Receives Grants to Advance Tuberculosis Treatment
Rhea-AI Summary
Evotec (NASDAQ:EVO) received two Gates Foundation grants totaling $9.9 million to support tuberculosis drug discovery and translational development over 24–25 months. The awards fund AI‑enabled discovery of novel small molecules and nonclinical evaluation of advanced TB drug combinations, including Long Acting Injectables, to accelerate candidate selection and de‑risk progression to clinical testing.
AI-generated analysis. Not financial advice.
Positive
- $4.9M grant over 25 months for TB small‑molecule discovery
- $5.0M grant over 24 months for nonclinical evaluation of TB combinations
- Use of AI‑enabled drug discovery to accelerate candidate selection
- Focus on Long Acting Injectables for transformative TB delivery options
Negative
- Grants fund preclinical and translational work; no clinical trial starts or dates disclosed
- Funding is time‑limited (24–25 months) and does not guarantee later‑stage clinical funding
News Market Reaction – EVO
On the day this news was published, EVO gained 5.78%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EVO was down 1.34% pre-news while key peers were mixed: AMPH +0.63%, DVAX +0.06%, HROW +0.35%, TLRY -4.66%, PCRX -0.44%. Movements do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 24 | CFO transition | Neutral | -2.5% | CFO Paul Hitchin stepping down; Claire Hinshelwood appointed as new CFO. |
| Apr 15 | COO appointment | Positive | +2.9% | Appointment of Dr. Ingrid Müller as COO to lead Horizon initiative execution. |
| Apr 07 | Chairman nomination | Positive | -1.5% | Nomination of Dieter Weinand as Supervisory Board Chairman at upcoming AGM. |
| Apr 01 | Earnings date set | Neutral | +1.6% | Announcement of date and webcast details for FY 2025 results release. |
| Apr 01 | CCO appointment | Positive | +1.6% | Appointment of Dr. Ashiq H. Khan as Chief Commercial Officer to drive deals. |
Recent news flow has centered on management and governance changes, with mostly modest single-day moves and one governance headline showing a negative divergence from its generally constructive tone.
Over the last month, Evotec’s news has focused on leadership and governance changes, including CFO, COO, CCO appointments and a proposed new Supervisory Board Chairman. These items produced small mixed price reactions, generally within a few percentage points. An earnings date announcement on April 8, 2026 also saw a mild positive move. Today’s TB grant announcement adds a scientific and partnership-focused milestone to what had been primarily management-related disclosures.
Market Pulse Summary
The stock moved +5.8% in the session following this news. A strong positive reaction aligns with the clearly constructive nature of these TB grants, which expand Evotec’s pipeline and leverage its AI-enabled discovery platforms. Historically, news on partnerships and leadership changes led to modest single-day moves within a few percent. Sustaining a larger gain could depend on how quickly these programs translate into concrete clinical milestones and whether subsequent updates maintain similar scientific and funding support.
Key Terms
ai-enabled drug discovery technical
long acting injectables medical
pharmacokinetics medical
clinical testing medical
clinical trials medical
nonclinical characterization medical
AI-generated analysis. Not financial advice.
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing
New funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens
HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to
The grant programs will expand the pipeline of novel TB drug candidates and advance the most promising combinations toward clinical evaluation, reducing development risk and accelerating progress toward a universal, shorter, safer and simpler TB drug regimen.
Although most TB patients can be cured with existing antibiotics, treatments are long, complex and difficult to complete, especially for drug-resistant forms of the disease leading to treatment failures. The new grants will enable Evotec to apply its state-of-the-art translational platforms, including AI-enabled drug discovery and translational evaluation, to discover and prioritize novel therapies that address these critical challenges.
The first grant supports Evotec's discovery efforts to advance a portfolio of novel small molecules with the potential to treat all TB patients. By combining its advanced AI‑enabled drug discovery platform with deep TB drug discovery expertise, Evotec aims to accelerate time to candidate selection and increase the likelihood of success, ultimately contributing to the development of improved treatment options.
The second grant enables the nonclinical characterization of next‑generation TB drug combinations proposed for late‑stage clinical trials, including those with potential for delivery as Long Acting Injectables. Long Acting Injectables represent a potentially transformative innovation in TB therapy. Using its cutting‑edge translational platforms, Evotec will generate data on pharmacokinetics, efficacy and resistance potential to inform optimal development pathways and de-risk progression to clinical testing.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said:
"We are grateful for the foundation's continued support. Effective TB drug development requires both a robust pipeline of novel candidates and rigorous translational evaluation to identify the combinations most likely to succeed in the clinic. These grants empower us to leverage our integrated AI-driven discovery and translational platforms to identify and advance the most promising candidates and combinations."
About Tuberculosis
Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis bacteria that primarily affects the lungs but can also impact other organs. Although curable with appropriate antibiotic regimens, the disease continues to impose a substantial global health burden, with an estimated 10.7 million new cases and 1.23 million deaths in 2024. Persistent challenges such as drug resistance and complex, burdensome treatment regimens highlight the need for improved diagnostics, shorter and safer therapies, and sustained investment in innovation.
Evotec has a strong presence in TB drug discovery and translational science and is an active participant in leading global collaborations across the philanthropic, non-profit and private sectors, including the TB Drug Accelerator (TBDA), ERA4TB, and the PAN-TB collaboration. Through these partnerships, Evotec contributes to the accelerated discovery and development of novel TB drugs and treatment regimens aimed at improving outcomes for patients worldwide.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire